Dallas-based Havencrest Capital Management has announced a majority investment in Tekton Research, LLC. According to data captured in the LevinPro HC database, this transaction represents the 25th clinical trials acquisition of 2023.
Founded in 2006 and headquartered in Austin, Texas, Tekton Research is a clinical trial site network with 23 sites across Texas, Colorado, Georgia, Kansas and Oklahoma. Tekton conducts clinical trials across several therapeutic areas, including vaccines and infectious disease, neurology, endocrinology, immunology and dermatology, among others.
Havencrest is a committed capital, lower middle-market private equity investment firm focused exclusively on the healthcare industry, especially in companies with EBITDA between $2 million and $10 million.
Jones & Spross served as legal counsel and Edgemont Partners served as financial advisor to Tekton. Bass, Berry & Sims served as legal counsel and Lincoln International served as financial advisor to Havencrest. Financial terms of the deal were not disclosed.
